Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury

Circulation

Volumn 90, Issue 2, 1994, Pages 944-951

  Shi, Yi ^a   Fard, Ali ^a   Galeo, Anthony ^a   Hutchinson, Howard G ^a   Vermani, Pawan ^a   Dodge, George R ^a   Hall, David J ^a   Shaheen, Farida ^a   Zalewski, Andrew ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

antisense oligomers; c myc; extracellular matrix; proto oncogenes; restenosis; smooth muscle cells

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; GROWTH INHIBITION; NONHUMAN; ONCOGENE C MYC; PLASMA CLEARANCE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; SWINE;

EID: 0027978302     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.2.944     Document Type: Article

References (47)

1. Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol. 1984;114: 79-93.
2. Mosse PRL, Campbell GR, Wang ZL, Campbell JH. Smooth muscle phenotypic expression in human carotid arteries. Lab Invest. 1985;53:556-562.
3. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;6:369-375.
4. Safian RD, Gelbfish JS, Erny RD, Schnitt SJ, Schmidt DA, Baim DS. Coronary atherectomy: clinical, angiographic, and histological findings and observations regarding potential mechanisms. Circulation. 1990;82:69-79.
5. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
6. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985; 56:139-145.
7. 1 during repair of arterial injury. J Clin Invest. 1991;88:904-910.
8. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.
9. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 1992;86: 538-547.
10. Shi Y, Hutchinson HG, Hall DJ, Zalewski A. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 1993;88: 1190-1195.
11. Biro S, Fu Y-M, Yu Z-X, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA. 1993;90:654-658.
12. Simons M, Edelman ER, DeKeyser J-L, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature. 1992;359:67-80.
13. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 1993;90:8474-8478.
14. Ross R. The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 1971;50:172-186.
15. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990; 82:2190-2200.
16. Schneider JE, Berk BC, Gravanis MB, Santoian EC, Cipolla GD, Tarazona N, Lassegue B, King SB. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. Circulation. 1993;88:628-637.
17. Kaddurah-Daouk R, Greene JM, Baldwin AS Jr, Kingston RE. Activation and repression of mammalian gene expression by the c-myc protein. Genes Dev. 1987;1:347-357.
18. Prendergast GC, Cole MD. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol Cell Biol. 1989;9:124-134.
19. Parkes JL, Cardell RR, Hubbard FC, Hubbard D, Meltzer A, Penn A. Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the c-myc proto-oncogene. Am J Pathol. 1991;138:765-775.
20. Miano JM, Tola RR, Vlasic N, Danishefsky KJ, Stemerman MB. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol. 1990;137:761-765.
21. Bauters C, de Groote P, Adamantidis M, Delcayre C, Hamon M, Lablanche JM, Bertrand ME, Dupuis B, Swynghedauw B. Protooncogene expression in rabbit aorta after wall injury: first marker of the cellular process leading to restenosis after angioplasty? Eur Heart J. 1992;13:556-559.
22. Campbell JH, Kocher O, Skalli O, Gabbiani G, Campbell GR. Cytodifferentiation and expression of α-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Arteriosclerosis. 1989;9:633-643.
23. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 1990;10:966-990.
24. Leclerc G, Isner JM, Kearney M, Simons M, Safian RD, Baim DS, Weir L. Evidence implicating nonmuscle myosin in restenosis. Circulation. 1992;85:543-553.
25. Simon M, Leclerc G, Safian RD, Isner JM, Weir L, Baim DS. Relationship between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. N Engl J Med. 1993;328:608-613.
26. Pickering JG, Weir L, Jekanowski J, Kearney MA, Isner JM. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J Clin Invest. 1993;91:1469-1480.
27. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 1993;73: 223-231.
28. Ang AH, Tachas G, Campbell JH, Bateman JF, Campbell GR. Collagen synthesis by cultured rabbit aortic smooth muscle cells: alteration with phenotype. Biochem J. 1990;265:461-469.
29. Stepp MA, Kindy MS, Franzblau C, Sonenshein GE. Complex regulation of collagen gene expression in cultured bovine aortic smooth muscle cells. J Biol Chem. 1986;261:6542-6547.
30. Kindy MS, Chang CI, Sonenshein GE. Serum deprivation of vascular smooth muscle cells enhances collagen gene expression. J Biol Chem. 1988;263:11426-11430.
31. Thompson CB, Challoner PB, Neiman PE, Groudine M. Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature. 1985;314:363-366.
32. Zamecnick PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280-284.
33. Helene C, Toulme J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta. 1990;1049:99-125.
34. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol. 1992;32:329-376.
35. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. J Med Chem. 1993;36:1923-1937.
36. Neckers L, Whitesell L, Rosolen A, Geselowitz DA. Antisense inhibition of oncogene expression. Crit Rev Oncogenesis. 1992;3: 175-231.
37. Smith RC, Bement WM, Dersch MA, Dvorkin-Rastl E, Dworkin MB, Capco DG. Nonspecific effects of oligodeoxynucleotide injection in Xenopus oocytes: a reevaluation of previous D7 mRNA ablation experiments. Genes Dev. 1988;2:1296-1306.
38. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA 1992;89:7305-7309.
39. Yaswen P, Stampfer MR, Ghosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev. 1993;3:67-77.
40. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science. 1993;261:1004-1012.
41. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992;355:564-566.
42. Iversen P. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anti-Cancer Drug Design. 1991;6:531-538.
43. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and the stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA. 1991;88:7595-7599.
44. Goodarzi G, Watabe M, Watabe K. Organ distribution and the stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharm Drug Disp. 1992;13:221-227.
45. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J. 1991;122:1136-1140.
46. Nunes GL, King SB, Hanson SR, Sahatjian RA, Scott NA. Hydrogel-coated PTCA balloon catheter delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation. 1992;86(suppl I):I-380. Abstract.
47. Cox DA, Anderson PG, Roubin GS, Chou C, Agrawal SK, Cavender JB. Effect of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries. Cor Art Dis. 1992;3:237-248.